CPhI Online

- Market News

Sanofi unveils EUROAPI as name of new European API company

12 Jan 2021

The new company, which will be the largest API player in the EU, with approximately €1 billion in expected sales by 2022, names Karl Rotthier as CEO

After announcing last February its plan to create a major European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), Sanofi has unveiled the new company name — EUROAPI.

The standalone company combines Sanofi’s API commercial and development activities with six of its European API production sites: Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France).

EUROAPI will contribute to supporting and securing API manufacturing as well as supply capacities for Europe and beyond.

Addressing recent increasing medicine shortages that critically affect patient care, the new API unit will ensure additional API supply capacities for Europe and beyond, and help balance the industry’s heavy reliance on API sourced from other regions, Sanofi said.

The new company, which is headquartered in France and boasts a broad portfolio of 200 APIs, will rank as the largest in the small molecules API market, and second largest on the global API market, with approximately €1 billion in expected sales by 2022.

EUROAPI will combine Sanofi’s API commercial and development activities with six of its European production sites: Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France).

By operating independently, the new entity plans to increase its sales to third parties and to expand its partnerships with other pharmaceutical companies in order to take advantage of new growth opportunities and have the ability to deftly adapt to customer needs, Sanofi said.

Sanofi has also announced the appointment of Karl Rotthier as the EUROAPI future CEO, effective 18 January. A seasoned leader with a strong API business experience, he was most recently the CEO of Centrient Pharmaceuticals.

Read More

Related Content